Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing

In this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on CDH6-directed antibody–drug conjugates (ADCs) such as raludotatug deruxtecan and other investigational agents. The discussion examines CDH6 expression in ovarian tumors, the current limitations of biomarker testing and patient selection, and how ADC characteristics, including target expression, payload, linker properties, and drug-to-antibody ratio, may influence efficacy. Experts also review early clinical activity and key toxicities associated with CDH6-directed ADCs, including cytopenias, gastrointestinal adverse events, fatigue, and interstitial lung disease, and emphasize monitoring and supportive care considerations. The conversation further explores unresolved questions about ADC sequencing, potential cross-resistance between agents sharing topoisomerase I inhibitor payloads, changes in tumor biomarker expression over time, and the potential role of repeat biopsy in guiding treatment selection as additional targeted therapies become available.